Molecular Partners Ag (MOLN) Interest Expenses (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Interest Expenses of -$14.05 for Q1 2026, up 98.88% year-on-year from -$7.06 in Q1 2025, and down 100.0% on a QoQ basis from $6.3 million in Q4 2025.
Molecular Partners Ag (MOLN) Interest Expenses (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Interest Expenses for 7 consecutive years, with -$14.05 the latest figure, recorded in Q1 2026.
- Quarterly Interest Expenses rose 98.88% year-over-year to -$14.05 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (up 17733.36% YoY) and the FY2025 annual result came in at $6.3 million, up 14457.33% from the prior year.
- Interest Expenses eased to -$14.05 in Q1 2026 per MOLN's latest filing, from $6.3 million in the prior quarter.
- Over the last five years, Interest Expenses for MOLN reached as high as $6.3 million in Q4 2025 and fell as low as -$1.3 million in Q2 2023.
- A 5-year average of $910682.9 and a median of -$12.45 in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses sank 23375.85% — and 2025, when it jumped 21145.8%.
- Year by year, Interest Expenses stood at $643111.7 in 2022, then jumped by 803.81% to $5.8 million in 2023, then sank by 99.25% to $43399.5 in 2024, then surged by 14450.09% to $6.3 million in 2025, then plunged by 100.0% to -$14.05 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered -$14.05, $6.3 million, and -$196.27 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 32.89 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 16.81 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 1.17 Bn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -14.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.05 |
| Mar 31, 2026 | -14.05 |
| Dec 31, 2025 | 6.31 Mn |
| Dec 31, 2025 | 6.31 Mn |
| Sep 30, 2025 | -196.27 |
| Sep 30, 2025 | -196.27 |
| Jun 30, 2025 | 4.23 Mn |
| Jun 30, 2025 | 4.23 Mn |
| Mar 31, 2025 | -1,259.07 |
| Mar 31, 2025 | -1,259.07 |
| Dec 31, 2024 | 43,399.52 |
| Dec 31, 2024 | 43,399.52 |
| Sep 30, 2024 | -2,923.61 |
| Sep 30, 2024 | -2,923.61 |
| Jun 30, 2024 | 19,904.28 |
| Jun 30, 2024 | 19,904.28 |
| Mar 31, 2024 | -11.46 |
| Mar 31, 2024 | -11.46 |
| Dec 31, 2023 | 5.81 Mn |
| Dec 31, 2023 | 5.81 Mn |